PMID- 36744246
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230207
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 14
DP  - 2023
TI  - Polydopamine-based loaded temozolomide nanoparticles conjugated by peptide-1 for 
      glioblastoma chemotherapy and photothermal therapy.
PG  - 1081612
LID - 10.3389/fphar.2023.1081612 [doi]
LID - 1081612
AB  - Purpose: Nanoparticles (NPs) of the polydopamine (PDA)-based,loaded with 
      temozolomide (TMZ) and conjugated with Pep-1 (Peptide-1) as a feasible nano-drug 
      delivery system were constructed and utilized for chemotherapy (CT) and 
      photothermal therapy (PTT) of glioblastoma (GBM). Method: PDA NPs were 
      synthesized from dopamine (DA) hydrochloride and reacted with TMZ to obtain the 
      PDA-TMZ NPs and then the PDA NPs and the PDA-TMZ NPs were conjugated and modified 
      by Pep-1 to obtain the Pep-1@PDA NPs and Pep-1@PDA-TMZ NPs via the Schiff base 
      reaction (SBR), respectively.Their dimensions, charge, and shape were 
      characterized by dynamic light scattering (DLS) and scanning electron microscope 
      (SEM). The assembly of TMZ was verified by Fourier-transform infrared 
      spectroscopy (FT-IR) and ultraviolet and visible spectroscopy (UV-Vis). The 
      biostability of both the nanocarrier and the synthetic NPs were validated using 
      water and fetal bovine serum (FBS). The antitumor activities of the PDA-TMZ NPs 
      and Pep-1@PDA-TMZ NPs were verified in U87 cells and tumor-bearing nude mice. 
      Results: The prepared PDA NPs, PDA-TMZ NPs, Pep-1@PDA NPs, and Pep-1@PDA-TMZ NPs 
      were regular and spherical, with dimension of approximately 122, 131, 136, and 
      140 nm, respectively. The synthetic nanoparticles possessed good dispersity, 
      stability,solubility, and biocompatibility. No obvious toxic side effects were 
      observed, and the loading rate of TMZ was approximately 50%.In vitro research 
      indicated that the inhibition ratio of the Pep-1@PDA-TMZ NPs combined with 808 nm 
      laser was approximately 94% for U87 cells and in vivo research was approximately 
      77.13%, which was higher than the ratio of the other groups (p < 0.05). 
      Conclusion: Pep-1 was conjugated and modified to PDA-TMZ NPs, which can serve as 
      a new targeted drug nano-delivery system and can offer a CT and PTT integration 
      therapy against GBM. Thus, Pep-1@PDA-TMZ NPs could be a feasible approach for 
      efficient GBM therapy, and further provide some evidence and data for clinical 
      transformation so that gradually conquer GBM.
CI  - Copyright (c) 2023 Wu, Zhang, Liu, Wei, Li, Ma, Wang, Zhu and Zhang.
FAU - Wu, Hao
AU  - Wu H
AD  - Graduate School of Dalian Medical University, Dalian, China.
AD  - Department of Neurosurgery, Clinical Medical College, Yangzhou University, 
      Yangzhou, China.
FAU - Zhang, Tianyi
AU  - Zhang T
AD  - Nanjing University, Nanjing, China.
FAU - Liu, Qi
AU  - Liu Q
AD  - Department of Neurosurgery, The First Hospital of Yu Lin, Yulin, China.
FAU - Wei, Min
AU  - Wei M
AD  - Graduate School of Dalian Medical University, Dalian, China.
AD  - Department of Neurosurgery, Clinical Medical College, Yangzhou University, 
      Yangzhou, China.
FAU - Li, Yuping
AU  - Li Y
AD  - Department of Neurosurgery, Clinical Medical College, Yangzhou University, 
      Yangzhou, China.
FAU - Ma, Qiang
AU  - Ma Q
AD  - Department of Neurosurgery, Clinical Medical College, Yangzhou University, 
      Yangzhou, China.
FAU - Wang, Lianhui
AU  - Wang L
AD  - Institute of Advanced Materials, Nanjing University of Posts and 
      Telecommunications, Nanjing, China.
FAU - Zhu, Yufu
AU  - Zhu Y
AD  - Department of Neurosurgery, The Affiliated Hospital of Xuzhou Medical University, 
      Xuzhou, China.
FAU - Zhang, Hengzhu
AU  - Zhang H
AD  - Department of Neurosurgery, Clinical Medical College, Yangzhou University, 
      Yangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20230118
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC9889548
OTO - NOTNLM
OT  - PEP-1
OT  - chemo/photothermal therapy
OT  - glioblastoma
OT  - nanoparticles
OT  - polydopamine
OT  - temozolomide
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/02/07 06:00
MHDA- 2023/02/07 06:01
PMCR- 2023/01/18
CRDT- 2023/02/06 04:07
PHST- 2022/10/27 00:00 [received]
PHST- 2023/01/03 00:00 [accepted]
PHST- 2023/02/06 04:07 [entrez]
PHST- 2023/02/07 06:00 [pubmed]
PHST- 2023/02/07 06:01 [medline]
PHST- 2023/01/18 00:00 [pmc-release]
AID - 1081612 [pii]
AID - 10.3389/fphar.2023.1081612 [doi]
PST - epublish
SO  - Front Pharmacol. 2023 Jan 18;14:1081612. doi: 10.3389/fphar.2023.1081612. 
      eCollection 2023.